Arcturus Therapeutics Holdings Inc. (ARCT) News
Filter ARCT News Items
ARCT News Results
|Loading, please wait...|
ARCT News Highlights
- 500 - Internal server error
- Over the past 18 days, the trend for ARCT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest ARCT News From Around the Web
Below are the latest news stories about Arcturus Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ARCT as an investment opportunity.
Global Familial Amyloid Polyneuropathy Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Pfizer, GSK, Ionis, Alnylam, Corino Therapeutics, Proclara Bioscience, Arcturus Therapeutics
The report on Global Familial Amyloid Polyneuropathy Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic 
SAN DIEGO, Calif., July 06, 2021--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
If You Had Bought Arcturus Therapeutics Holdings (NASDAQ:ARCT) Stock Three Years Ago, You Could Pocket A 285% Gain Today
It hasn't been the best quarter for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders, since the share...
During Q1, Arcturus Therapeutics ''s (NASDAQ: ARCT ) reported sales totaled $2.13 million. Despite a 85.53% in earnings, the company posted a loss of $57.67 million. In Q4, Arcturus Therapeutics brought in $2.24 million in sales but lost $31.08 million in earnings. What Is Return On Capital Employed? Changes in earnings and sales indicate shifts in Arcturus Therapeutics''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and Full story available on Benzinga.com
In Q1, Arcturus Therapeutics (NASDAQ: ARCT ) posted sales of $2.13 million. Earnings were up 85.53%, but Arcturus Therapeutics still reported an overall loss of $57.67 million. Arcturus Therapeutics collected $2.24 million in revenue during Q4, but reported earnings showed a $31.08 million loss. What Is Return On Capital Employed? Changes in earnings and sales indicate shifts in Arcturus Therapeutics''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a Full story available on Benzinga.com
These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer.
Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics
Primordial Genetics ("Primordial"), a synthetic biology company developing enzymatic production systems for nucleic acids, today announced granting Arcturus Therapeutics Holdings Inc. ("Arcturus", Nasdaq: ARCT), a clinical-stage messenger RNA (mRNA) medicines company, an exclusive license of an enzyme for an RNA polymerase (RNApol)
The big shareholder groups in Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) have power over the company...
Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by Barclays from $46.00 to $33.00 in a research note published on Tuesday, The Fly reports. The brokerage currently has an equal weight rating on the biotechnology companys stock. A number of other equities analysts have also issued reports on ARCT. Zacks Investment Research upgraded Arcturus Therapeutics 
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.